Raymond James analyst Michael Freeman upgraded NervGen Pharma (NGENF) to Outperform from Market Perform with a price target of C$4.50, up from C$3.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGENF: